银屑病关节炎中血清CRP与IL-17A/IL-17F对乌司奴单抗的反应性
基于两项PSUMMIT III期研究(n=927)的事后分析,评估银屑病关节炎患者血清CRP及Th17相关细胞因子与疾病活动度和乌司奴单抗疗效的关联。基线IL-17A/IL-17F与皮肤病变评分正相关,但与关节活动度及治疗反应无关;乌司奴单抗治疗后CRP、IL-17A、IL-17F显著下降,应答者CRP降幅更大。
要点
- 基线IL-17A/IL-17F与皮肤评分正相关,与关节活动度无关。
- 基线Th17细胞因子或CRP水平不能预测乌司奴单抗皮肤或关节应答。
- 乌司奴单抗治疗后CRP、IL-17A、IL-17F较安慰剂显著下降。
核心结论
- 基线血清IL-23/IL-17水平与皮肤而非关节疾病活动度相关,提示组织特异性差异。
- 基线Th17相关细胞因子或CRP水平均不能预测乌司奴单抗在皮肤或关节的疗效。
- 乌司奴单抗治疗后CRP、IL-17A、IL-17F水平快速下降。
研究设计与样本
- 两项PSUMMIT III期、多中心、双盲、安慰剂对照研究的事后分析,共927例银屑病关节炎患者。
- 检测血清IL-17A、IL-17F、IL-23和CRP浓度,用广义线性模型和Pearson相关分析评估基线与第4周、第24周水平与疾病活动度及治疗反应的关系。
主要发现
- 基线IL-17A和IL-17F与基线皮肤疾病评分正相关(r=0.39-0.62),IL-23相关性较弱(r=0.26-0.31)。
- 这些细胞因子或CRP水平与基线关节疾病活动度无显著相关性。
- 基线IL-17A、IL-17F、IL-23或CRP水平与乌司奴单抗皮肤或关节治疗反应无显著关联。
- 乌司奴单抗治疗患者较安慰剂组IL-17A、IL-17F和CRP水平较基线显著下降。
- 第24周达到PASI 75或ACR 20的乌司奴单抗治疗患者CRP几何均值下降51-58%,未应答者下降32-33%(P<0.05),但IL-17A或IL-17F水平无此差异。
关键数值与推荐
- 基线IL-17A/IL-17F与皮肤评分相关系数r=0.39-0.62,IL-23为r=0.26-0.31。
- 第24周应答者CRP几何均值下降51-58%,非应答者下降32-33%(P<0.05)。
临床怎么用
- 基线Th17细胞因子或CRP不宜作为乌司奴单抗皮肤或关节疗效的预测指标。
- 治疗中CRP下降幅度可能与皮肤或关节应答相关,但IL-17A/IL-17F下降无此关联。
局限性
- 为事后分析,非预设主要终点。
- 仅报告相关性,未明确因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the associations of C-reactive protein (CRP) and circulating Th17-associated cytokine levels with psoriatic arthritis (PsA) disease activity and therapeutic response to ustekinumab. METHODS: Interleukin-17A (IL-17A), IL-17F, IL-23, and CRP concentrations were measured in serum samples collected as part of the 2 PSUMMIT phase III studies of ustekinumab in PsA (n = 927). In post hoc analyses, relationships of IL-17A, IL-17F, and CRP levels at baseline, week 4, and week 24 with baseline skin and joint disease activity and response to therapy were evaluated using generalized linear models and Pearson's product-moment correlation tests. RESULTS: Baseline serum levels of IL-17A and IL-17F were positively correlated with baseline skin disease scores (r = 0.39-0.62). IL-23 levels were correlated with skin disease scores to a lesser extent (r = 0.26-0.31). No significant correlations were observed between these cytokine or CRP levels and baseline joint disease activity. There was no significant association of baseline levels of IL-17A, IL-17F, IL-23, or CRP with therapeutic response to ustekinumab in either the skin or joints. Significant reductions from baseline in levels of IL-17A, IL-17F, and CRP were seen in patients treated with ustekinumab compared to those treated with placebo. Ustekinumab-treated patients in whom 75% improvement in the Psoriasis Area and Severity Index score or 20% improvement according to the American College of Rheumatology criteria was achieved after 24 weeks of treatment had greater reductions in CRP level (geometric mean decreases of 51-58% versus 32-33%; P < 0.05), but not IL-17A or IL-17F levels, than nonresponders. CONCLUSION: Baseline serum IL-23/IL-17 levels correlated with skin, but not joint, disease activity, suggesting tissue-specific variation. However, neither baseline Th17-associated cytokine levels nor CRP level were predictive of therapeutic response to ustekinumab in the skin or joints, despite rapid reductions in their levels following ustekinumab therapy.
引用
- Siebert S, Sweet K, Dasgupta B, et al. Responsiveness of Serum C-Reactive Protein, Interleukin-17A, and Interleukin-17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double-Blind, Placebo-Controlled Trials. Arthritis Rheumatol. 2019. PMID: 31070869. doi:10.1002/art.40921
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。